BE1002966A5 - Compositions pharmaceutiques. - Google Patents

Compositions pharmaceutiques. Download PDF

Info

Publication number
BE1002966A5
BE1002966A5 BE8901158A BE8901158A BE1002966A5 BE 1002966 A5 BE1002966 A5 BE 1002966A5 BE 8901158 A BE8901158 A BE 8901158A BE 8901158 A BE8901158 A BE 8901158A BE 1002966 A5 BE1002966 A5 BE 1002966A5
Authority
BE
Belgium
Prior art keywords
pharmaceutical compositions
pharmaceutically acceptable
composition
hypertensions
alanyl
Prior art date
Application number
BE8901158A
Other languages
English (en)
Original Assignee
Fisons Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Plc filed Critical Fisons Plc
Application granted granted Critical
Publication of BE1002966A5 publication Critical patent/BE1002966A5/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Composition pharmaceutique qui comprend de l'acide 5-t-butyl-3-[N-(1-(S)-éthoxycarbonyl-3-phénylpropyl)-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2-(S)-carboxylique, ou un sel, ester ou amide pharmaceutiquement acceptable de celui-ci, en mélange avec un adjuvant, diluant ou excipient pharmaceutiquement acceptable. Avantageusement, la composition sa prête au façonnage en comprimés ou au conditionnement dans des capsules et permet le traitement d'hypertensions de diverses origines.
BE8901158A 1988-11-01 1989-10-31 Compositions pharmaceutiques. BE1002966A5 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888825541A GB8825541D0 (en) 1988-11-01 1988-11-01 Formulation

Publications (1)

Publication Number Publication Date
BE1002966A5 true BE1002966A5 (fr) 1991-10-08

Family

ID=10646121

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8901158A BE1002966A5 (fr) 1988-11-01 1989-10-31 Compositions pharmaceutiques.

Country Status (12)

Country Link
EP (1) EP0367509A3 (fr)
JP (1) JPH02172917A (fr)
BE (1) BE1002966A5 (fr)
CA (1) CA2001906A1 (fr)
CH (1) CH679554A5 (fr)
DK (1) DK541789A (fr)
FR (1) FR2638642A1 (fr)
GB (2) GB8825541D0 (fr)
GR (1) GR1000437B (fr)
IE (1) IE893502L (fr)
LU (1) LU87616A1 (fr)
PT (1) PT92167A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
SE9700135D0 (sv) † 1997-01-20 1997-01-20 Astra Ab New formulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2838387A1 (de) * 1978-05-16 1979-10-31 Lilly Industries Ltd Zusammensetzung zum fuellen von kapseln
US4178374A (en) * 1974-08-16 1979-12-11 Merck & Co., Inc. Novel pharmaceutical compositions of β-blockers with diuretics
EP0105996A1 (fr) * 1982-10-15 1984-04-25 Merck & Co. Inc. Compositions ophtalmiques pour le traitement de la pression intraoculaire élevée
EP0217519A1 (fr) * 1985-08-31 1987-04-08 FISONS plc Inhibiteurs de l'enzyme de conversion de l'angiotensine hétérocycliques à 5 chaînons

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178374A (en) * 1974-08-16 1979-12-11 Merck & Co., Inc. Novel pharmaceutical compositions of β-blockers with diuretics
DE2838387A1 (de) * 1978-05-16 1979-10-31 Lilly Industries Ltd Zusammensetzung zum fuellen von kapseln
EP0105996A1 (fr) * 1982-10-15 1984-04-25 Merck & Co. Inc. Compositions ophtalmiques pour le traitement de la pression intraoculaire élevée
EP0217519A1 (fr) * 1985-08-31 1987-04-08 FISONS plc Inhibiteurs de l'enzyme de conversion de l'angiotensine hétérocycliques à 5 chaînons

Also Published As

Publication number Publication date
CH679554A5 (fr) 1992-03-13
GB8924207D0 (en) 1989-12-13
GR890100710A (en) 1990-12-31
DK541789D0 (da) 1989-10-31
GB2224206A (en) 1990-05-02
EP0367509A2 (fr) 1990-05-09
DK541789A (da) 1990-05-02
PT92167A (pt) 1990-05-31
GR1000437B (el) 1992-07-30
CA2001906A1 (fr) 1990-05-01
GB2224206B (en) 1992-12-09
FR2638642A1 (fr) 1990-05-11
IE893502L (en) 1990-05-01
JPH02172917A (ja) 1990-07-04
GB8825541D0 (en) 1988-12-07
EP0367509A3 (fr) 1991-05-15
LU87616A1 (fr) 1991-07-22

Similar Documents

Publication Publication Date Title
CA2059865C (fr) Compositions pharmaceutiques contenant des glycosaminoglycans absorbables par voie orale
CA2201264A1 (fr) Forme posologique solide de cisapride, independante du ph et a liberation immediate
CA2258095A1 (fr) Compositions contenant de la tetrahydrolipstatine
KR910011894A (ko) 아미노산 유도체
CA2004239A1 (fr) Utilisation de l'acetyl-d-carnitine dans le traitement therapeutique du glaucome et composes pharmaceutiques utiles dans un tel traitement
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
TW262461B (fr)
EP0655459A3 (fr) Procédé d'introduction d'une double-liaison 1,2 dans les stéroides-4aza, et Proscor(R) cristallin et compositions pharmaceutiques le contenant.
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
RU93047023A (ru) Производные имидазола-антагонисты ангиотензина-11, их получение и терапевтическое применение
IL92797A0 (en) Therapeutical active substituted benzimidazole and process for its preparation
CA2032475A1 (fr) Preparations pharmaceutiques pour administration par voie orale permettant la liberation du medicament dans des endroits cibles de l'intestin
FR2618331B1 (fr) Compositions pharmaceutiques utiles pour le traitement de l'uremie
BE1002966A5 (fr) Compositions pharmaceutiques.
NAGAI et al. Liver injury model in mice for immunopharmacological study
BE1002504A3 (fr) Preparation medicamenteuse a base de derives d'esters d'hecogenine et leur utilisation pour le traitement de l'hyperplasie prostatique benigne.
FR2627084B1 (fr) Formes galeniques solides contenant une ou plusieurs substances peroxydiques liberant de l'oxygene actif et utilisees en hygiene bucco-dentaire ou comme decontaminants de lentilles ophtalmiques
ITMI940931A0 (it) Procedimento per la preparazione di particelle lavorate a secco, particelle lavorate a secco cosi' ottenute e composizioni farmaceutiche contenenti le particelle
NO174198C (no) Analogifremgangsmåte for fremst.av den terapeutisk aktive forbindelse 3-metoksy-4-(1-metyl-5-(2-metyl-4,4,4-trifluorbutylkarbamoyl)indol-3-ylmetyl)-N-(2-metylfenyl-sulfonyl)benzamid, eller et farmasöytisk akseptabelt salt derav
SE8600496L (sv) Farmaceutiska kompositioner innehallande 9,10-dihydroergotalkaloider
ZA894945B (en) Strontium salt,process for the preparation thereof and pharmaceutical compositions containing it
BE1002255A5 (fr) Medicaments.
RU95110494A (ru) Средство с регулируемым высвобождением пентоксифиллина для лечения сосудистых заболеваний
GR3005736T3 (fr)
EA200101108A1 (ru) Полиморфные модификации кристаллического цитрата азабицикло[2.2.2]октан-3-амина и их фармацевтические композиции

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: FISONS PLC.

Effective date: 19931031